How Long Does It Take for an Allergy Shot to Work? One Dose vs. Full Treatment

A flu shot and an allergy immunotherapy shot work through very different mechanisms. A flu vaccine contains killed or weakened influenza virus antigens and leverages your already-functioning adaptive immune system to produce protective antibodies over 2 weeks with a single dose, because the immune system only needs to recognize and remember a pathogen it hasn't seen. Allergy immunotherapy works differently: it attempts to re-educate an immune system that has already been mis-programmed to treat harmless substances as threats. Undoing years of Th2 immune bias — the allergic response — requires persistent, repeated allergen exposure over months to years to shift the immune system toward regulatory T cell tolerance. One injection delivers enough allergen to begin that process microscopically but not enough to produce the sustained T-cell regulatory shift that translates into clinical benefit. The better analogy is a vaccine series like hepatitis B, which requires 3 doses over 6 months to produce full protection — immunotherapy simply requires 60-80+ doses over 3-5 years.

The typical answer from clinical practice and research is that patients begin noticing some symptom improvement 3-6 months after reaching the maintenance dose — a dose that itself takes 8-28 weeks of build-up injections to reach. In practical terms, most patients receiving conventional weekly injections reach maintenance at around week 25-30, meaning first perceivable benefit often appears at roughly 10-18 months after beginning treatment. The earliest measurable sign — reduced rescue antihistamine use — can appear within 6 months of maintenance (Calderon et al., Cochrane 2007). Full efficacy continues accumulating through 3 years of maintenance. Patients who show zero improvement after one full year at maintenance dose should discuss with their allergist whether dose, allergen selection, or treatment approach needs reevaluation, per AAAAI Practice Parameters.

A temporary increase in local injection-site reactions during build-up is common and expected — the escalating allergen doses produce progressively larger local reactions as a normal part of the process. However, generalized worsening of allergy symptoms throughout the body is not an expected effect of immunotherapy and could indicate a dose that needs adjustment. Patients starting SCIT during or immediately before their relevant pollen season may have a more difficult build-up because they're simultaneously experiencing natural allergen challenge on top of injection-related immune stimulation. Allergists often reduce injection doses during a patient's peak pollen season (approximately 40% of US practices reduce doses during peak season, per Larenas-Linnemann 2012) to manage this overlap. If you feel like your overall allergy control is noticeably worse than before starting shots, discuss this with your allergist — it is worth evaluating whether dose adjustment is warranted rather than assuming it's an expected temporary worsening.

Early discontinuation driven by unmet expectations of rapid relief is one of the most documented causes of SCIT treatment failure. The largest real-world adherence study (Kiel et al., JACI 2013) found that only 23% of allergy shot patients completed the minimum recommended 3-year course, with median treatment duration of just 1.7 years. Patient survey research (Kiel 2013) identified perceived ineffectiveness — often meaning no quick relief — as one of the top reasons for dropout, alongside inconvenience and cost. Patients who receive realistic expectation counseling before starting SCIT have significantly better adherence: research suggests patients informed of the 12-18 month timeline upfront have approximately 30% lower dropout rates than those expecting quicker results. Stopping before completing 2 years produces little to no sustained benefit; stopping after 2 years shows some benefit but with higher relapse rates than completing 3+ years per Naclerio et al. (JACI 1997).

There is no established method to dramatically accelerate the immunologic timeline of conventional SCIT, but one structural option may help reach maintenance faster: accelerated protocols. Cluster immunotherapy — which administers 2-3 injections per visit on non-consecutive days — can reach the maintenance dose in 4-8 weeks rather than the conventional 8-28 weeks, with approximately 50% fewer build-up visits (Calabria, Ann Allergy Asthma Immunol 2023). Rush immunotherapy compresses build-up further to 1-3 days, though it carries higher systemic reaction rates and requires hospital-level monitoring. Both approaches accelerate only the build-up phase — the 3-5 year maintenance phase recommendation does not change. Additionally, starting SCIT outside your relevant pollen season allows unimpeded dose escalation, potentially producing perceptible benefit in your very first treated season rather than your second. Omalizumab (anti-IgE) pretreatment has been studied as a way to safely accelerate rush immunotherapy in high-risk patients (Casale et al., JACI 2006), though this is not standard practice outside high-reactivity cases.

The first allergy shot is among the lowest-dose injections you will ever receive — starting at 1,000- to 10,000-fold dilution of the eventual maintenance dose — so in terms of immune challenge, it is actually the most dilute and safest injection of your course. Patients typically tolerate first build-up injections very well, with minimal injection-site reactions and no systemic effects. The injections that require the most careful management are those in the mid-to-late build-up phase, where doses are escalating toward maintenance concentrations and the immune challenge is at its highest. The first injection can feel psychologically challenging for needle-anxious patients, and the observation period may feel long and unfamiliar. Physically, however, most patients report the first injection is a relatively minor experience — a small subcutaneous needle in the upper arm, similar in sensation to a routine blood draw or vaccine. The 30-minute observation that follows is the most time-consuming part of the first appointment.